Author: Zacks Small Cap Research

1 2 3 30 10 / 299 POSTS
By Brian Marckx, CFANASDAQ:MNKDREAD THE FULL MNKD RESEARCH REPORTZacks SCR analysts Brian Marckx, CFA and Anita Dushyanth, PhD have initiated coverage of MannKind Corporation with a $4.25/share price target. See above for free access to our 36-page r ...
OTC:ALPEAlpha-En Corp (OTC:ALPE) is a technology development company focused on enabling next-generation battery technologies through the development of processes that target significant performance advances for lithium batteries, specifically the pr ...
By Steven Ralston, CFAOTC:GRWGREAD THE FULL GRWG RESEARCH REPORTEXECUTIVE SUMMARY OF RECENT EVENTSIn the third quarter of 2018, sales increased 109% to approximately $8.41 million versus $4.03 million during the comparable quarter in 2017. Working ca ...
By John Vandermosten, CFANASDAQ:AZRXREAD THE FULL AZRX RESEARCH REPORTOn November 9th, AzurRx BioPharma, Inc. (NASDAQ:AZRX) filed its third quarter 10-Q with the SEC for the three month period ending September 30, 2018. Highlights for the period and ...
By John Vandermosten, CFANASDAQ:PHIOREAD THE FULL PHIO RESEARCH REPORTPHIO Pharmaceuticals Corp. (NASDAQ:PHIO) reported third quarter results and filed its Form 10-Q on November 14, 2018. The company disclosed its quarterly performance and highighted ...
By John Vandermosten, CFATSE:PMN.TO | OTC:ARFXFREAD THE FULL PMN.TO RESEARCH REPORTThird Quarter 2018 Results ProMIS Neurosciences Inc. (TSE:PMN.TO) (OTC:ARFXF) has experienced a busy quarter since our previous report providing presentations and pres ...
By Brian Marckx, CFANASDAQ:EYEG | NYSE:AGNREAD THE FULL EYEG RESEARCH REPORTQ3 Financial Results, Operating Update…EyeGate (NASDAQ:EYEG) announced Q3 financial results and provided a business update. In terms of the financials, milestone from the EGP ...
By Brian Marckx, CFANASDAQ:CEMIREAD THE FULL CEMI RESEARCH REPORTQ3 2018: Record YTD revenue, margins take a hit but should begin to rebound…Chembio (NASDAQ:CEMI) reported financial results for their third quarter ending September 30, 2018. Q3 made i ...
By David Bautz, PhDTSX:ATE.VREAD THE FULL ATE.V RESEARCH REPORTBusiness UpdatePart 1 of Phase 2b Dose-Ranging, Efficacy Study Successfully CompletedOn November 27, 2018, Antibe Therapeutics, Inc. (TSX:ATE.V) announced that it has successfully complet ...
By Brian Marckx, CFANASDAQ:VIVEREAD THE FULL VIVE RESEARCH REPORTQ3 Results: Results Inline But FDA-Action vs. Competitors Could Create Short-Term Headwind. Long-Term Outlook Intact…Viveve (NASDAQ:VIVE) reported Q3 2018 financial results and provided ...
1 2 3 30 10 / 299 POSTS